We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
REDWOOD-HCM Topline Results
Jul 19, 2021 8:30 AM EDT
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>
SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 30, 2021 it granted stock options to purchase an aggregate of 258,750 shares of common stock to 15 new employees, whose employment commenced in July 2021 , as a
Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Decline of SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo Company Is Planning to Provide Continued Access to Patients Who Complete COURAGE-ALS and Patients Who Previously Participated in Cytokinetics
SOUTH SAN FRANCISCO, Calif. , July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $27.50 per share.
SOUTH SAN FRANCISCO, Calif. , July 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 5, 2021 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
